PR
XENE icon

PSP Research’s Xenon Pharmaceuticals XENE Stock Holding History

PSP Research’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Hold
4,200
– – 0.13% 57
2026
Q1 		$244K Sell
4,200
-7,478
-64% -$345K 0.17% 64
2025
Q4 		$523K Buy
+11,678
New +$490K 0.46% 60

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

PSP Research's XENE Position: Q2 2026 in Review

PSP Research held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 4,200 shares worth $254K. The position accounts for 0.13% of the portfolio, ranked #57.

PSP Research first reported a position in XENE in Q4 2025 and has held it in 3 quarters since. The position peaked at $523K in Q4 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • PSP Research held 4,200 shares of Xenon Pharmaceuticals worth $254K as of Q2 2026.
  • PSP Research left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
  • Xenon Pharmaceuticals made up 0.13% of PSP Research's portfolio in Q2 2026, its #57 holding.
  • PSP Research first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Xenon Pharmaceuticals position peaked at $523K in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.